DMNB

• UNSPSC Description:

  DMNB (6-Nitroveratraldehyde), a precursor, can be used for the synthesis no-carrier-added 6-[18F]fluoro-L-DOPA (6-FDOPA). No-Carrier-Added (NCA) 6-[18F]fluoro-L-dopa (6-FDOPA) is being produced routinely for PET investigations of dopaminergic systems[1].

• Target Antigen:

  Others

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/dmnb.html

• Purity:

  99.38

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=CC1=CC(OC)=C(OC)C=C1[N+]([O-])=O

• Molecular Weight:

  211.173

• References & Citations:

  [1]Zhang Lan, et al. Preparation of 6-[¹⁸F]fluoro-L-DOPA and its biodistribution in normal and unilateral PD model rats. Nuclear Science and Techniques, 13(4), 244-250.|[2]Reddy GN, et al. Quality assurance and quality control methods for animal and human applications of no-carrier-added 6-[18F]fluorodopa for PET investigations of dopaminergic systems. Appl Radiat Isot. 1993;44(7):993-998.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Clinical Information:

  No Development Reported

• CAS Number:

  20357-25-9